Product of interest
PandaOmics
PandaOmics Box
Chemistry42
Generative Biologics
Science42:DORA
inClinico
I agree to
Privacy Policy
Required Field
Please enter a valid email address
Please enter a valid name
Please enter a valid phone number
Value is too small
Send Request
Required Field
Please enter a valid email address
Please enter a valid name
Please enter a valid phone number
Value is too small
Main
About
Mission
Leadership
Board of Directors
Scientific Advisory Board
Contact us
Pharma.ai
Pharma.ai Suite
PandaOmics
Generative Biologics
Chemistry42
inClinico
Science42: DORA
Nach01
Pipeline
News & Media
Press Releases
Blog
Media Coverage
Publications
Media Kit
Design Kit
Careers
Docuthon
PreciousGPT
Sustainability
EN
_
FR
Main
About
Mission
Leadership
Board of Directors
Scientific Advisory Board
Contact us
Pharma.ai
Pharma.ai Suite
PandaOmics
Generative Biologics
Chemistry42
inClinico
Science42: DORA
Nach01
Pipeline
News & Media
Press Releases
Blog
Media Coverage
Publications
Media Kit
Design Kit
Careers
Docuthon
PreciousGPT
Sustainability
Chemistry42
Biology42
开放对外授权
适应症
II期临床
I期临床
IND-enabling
先导化合物
优化
Hit-to-lead
靶点发现
另有20+创新项目处于药物发现阶段
Medicine42
Science42
Large Language of Life Models (LLLMs)
LLM Assistant
联系我们
生成式人工智能软件驱动药物研发、
科学研究和可持续发展
科研辅助软件
生成式AI和机器人技术驱动发现的
高质量药物管线
药物管线组合
想了解更多有关Pharma.AI的信息吗?
Generative AI and Robotics
for Longevity and Sustainability
我们的使命是
为所有人创造
更健康、更长寿的未来
通过生成式人工智能变革药物研发流程,
赋能更高效、更经济的创新药物研发解决方案,
与业界携手满足患者之需
联系我们
加入我们
疾病模型与靶点发现课程
免费注册报名
现在参与
×
英矽智能如何从早期蛋白质建模到达AI 赋能药物研发
“不确定性带来机遇。通过数据和巧妙的筛选,我们将不确定性转化为确定性和机遇”,Levitt 博士已看到未来的广阔前景,“50 年来一直困扰科学界的蛋白质折叠问题以及药物设计难题,如今都正在以这种全局性、全方位的方式得到解决。我个人非常看好此技术的前景。”
Michael Levitt 博士
美国斯坦福大学终身教授、英矽智能科学顾问委员会成员,因利用计算机建模研究蛋白质结构和蛋白质折叠取得开创性成就,荣获2013年诺贝尔化学奖。
在这个讲座中,Levitt 博士介绍了 50 年以来计算机速度的大幅提升和机器学习的惊人进步如何提升和帮助了他的研究。他谈到了 OPUS-X 和 AlphaFold,以及相关技术贡献对人类能力和认识的提高。
Levitt 博士表示,英矽智能正在创建从头开始由人工智能驱动的创新药物发现解决方案。以识别疾病出发,训练人工智能做它最擅长的事情——分析从许多组件中获得的大量数据,从而发现潜在的靶点并从头设计新分子。
新闻中心
阅读更多 →
媒体报道
阅读更多 →
学术发表
阅读更多 →
Most innovative biotechnology company in the world 2024
Read Full
About Insilico
TNIK
TNIK Inhibitor: Treating Fibrotic diseases of the Lung and Kidney
USP1
Ubiquitin Specific Protease 1 (USP1) Inhibitor for the treatment of BRCA-mutant cancer
QPCTL
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) Inhibitor: Novel cancer immunotherapy for COLD tumors
PHD
Proline Hydroxylase (PHD) Inhibitors: Treatment of Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD)
MAT2A
Methionine adenosyltransferase 2α (MAT2A) Inhibitor: Treatment of MTAP Deficient Cancer
TEAD
Pan-TEAD Inhibitor: Treating Mesothelioma, and Solid Tumors
ENPP1
Ectonucleotide phosphodiesterase 1 (ENPP1) Inhibitor: Treating anti-PD-1/-L1 resistant cancers
KAT6
KAT6 Inhibitor: Treatment of ER+/HER2- Breast Cancer
DGKA
Diacylglycerol kinase A (DGKA) Inhibitor: Treating solid tumors in combination with checkpoint inhibitor
CDK12
Cyclin-dependent kinase 12 (CDK12) Inhibitor: Treating Tumors by Induction of BRCAness
FGFR2/3
FGFR2/3 Dual Inhibitor: Treatment of Solid Tumors
KIF18A
KIF18A Inhibitor: Treating chromosomally unstable cancers with TP53 mutations
3CLPro
Orally Available covalent irreversible 3CLPro Inhibitor for the Treatment of COVID-19 and Coronavirus infection